Thread by @tycoonmindset05

Cadila Healthcare Concall was today at 6:15 PM.

Here are key highlights of the Conference Call😀

-Human health and consumer wellness business has seen improvement and is expected to grow in coming quarters.

-Animal health care segment grew by double digit in YoY basis.

- 40% reduction in Net debt as compared to March 2020

- Generics business grew because of Volume expansion.

- Pharmaceutical segment in India: Human health formulation is up 11% in YoY basis.

- Drug discovery : phase 1 completed of the Covid vaccine.
For phase 2, company completed enrollment of 1000 patients. Company will partner with MNC to make the vaccine available to the emerging countries.

- India business: Very strong recovery both on QoQ & YoY. Chronic portfolio is very strong. Acute segment is growing slowly.

- Specialty segment has registered a double digit growth. Marketing activity is still limited but marketing is being done on certain segment of portfolio

- Marketing will normalize as sales normalize. As it is still difficult to reach the doctors in all the segments.

- On the base business company continues to do well, there is a growth in volume

- Good working capital management has helped the company. Better cash management and lower cost has let to improvement in cash and overall debt reduction.

-In R&D, company will spend in H2 and next year company 7-8% of revenue.

- Actively there are 10-11 products in licensing phase. 1 is in early stage.

- India: Generic growth in India was muted, if this data was removed then growth number will be better.

- Animal health case segment: Rural economy recovering better at a better rate. Poultry business also growing at a good rate. Company's good product mix and good brands helped the company.

-In API company is not a large player, but due to good product and cost it is seeing good attraction of demand .

- Govt have discontinued msme scheme, company is not getting export benefit, new scheme will be launched by next year.

- Remdesivir
Company has good supply of Remdesivir. Company has been providing it at the lowest rate. Company is not exporting it so that market is also open.

- 70% increase in manufacturing capacity for vaccine can be used for other vaccines as well.

- Company will be partnering with MNCs for manufacturing and distribution of vaccine.

- Scale up process varies between 4-6 month depending upon the platform and technology.

- Company has a good market share in Remdesivir as it is low priced good quality product and easily available even with a chemist.

- Remdesivir has been approved as a first line medicine by USFDA, for treatment for moderate to Sever treatment.

- Specialty and chronic segment has done very well.

- Company has to drive the growth where there is a growth in market. This is possible for company has company has strong R&D.

- Cadila had a strong COVID portfolio, company has focused on new launches which will do well for the company

- Acute portfolio is not doing so well but company is not extensively present in Acute segment.

- For next 2 quarters, good growth is expected in domestic business.

- Company is building Brands, making new launches and providing digital services which will help the company in gaining presences in doctors chamber.

- Injectable: Company is making progress in this market. They are getting approval from regulators. Company expects this segment will be worth $150-200 million in next 3-4 years.

- Filing run rate: company will be filing for more than 30 ANDAs in this year, next year company is expecting to file 40-45 ANDAs. In H1 company filed for 10 ANDAs.

Refer to our Q2 FY 2021 conference call here👇👇

thetycoonmindset.com/conference-cal…